NCT04929028 2026-03-18Therapy Adapted for High Risk and Low Risk HIV-Associated Anal CancerNational Cancer Institute (NCI)Phase 2 Recruiting40 enrolled
NCT07140679 2025-09-25Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon CancerEmory UniversityPhase 2 Recruiting40 enrolled